{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:43:12Z","timestamp":1780461792900,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05734-3","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T08:05:18Z","timestamp":1618992318000},"page":"4039-4047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry"],"prefix":"10.1007","volume":"40","author":[{"given":"Marco","family":"Sebastiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Biggioggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Petricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Visalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Contributors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lomater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Salaffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"5734_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"FH Epstein","year":"1990","unstructured":"Epstein FH, Harris ED (1990) Rheumatoid arthritis. N Engl J Med 322:1277\u20131289","journal-title":"N Engl J Med"},{"key":"5734_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"5734_CR3","first-page":"S148","volume":"22","author":"EC Keystone","year":"2004","unstructured":"Keystone EC (2004) Safety issues related to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol 22:S148\u2013S150","journal-title":"Clin Exp Rheumatol"},{"key":"5734_CR4","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"5734_CR5","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1136\/annrheumdis-2014-205325","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73:2174\u20132177","journal-title":"Ann Rheum Dis"},{"key":"5734_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jbspin.2012.09.023","volume":"80","author":"A Pierreisnard","year":"2013","unstructured":"Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T (2013) Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Jt Bone Spine 80:386\u2013392","journal-title":"Jt Bone Spine"},{"key":"5734_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001395","volume":"2","author":"P Jobanputra","year":"2012","unstructured":"Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, Faizal A, Goddard C, Pugh M, Bowman SJ, Brailsford S, Nightingale P (2012) A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2:e001395","journal-title":"BMJ Open"},{"key":"5734_CR8","doi-asserted-by":"publisher","first-page":"831603","DOI":"10.1155\/2014\/831603","volume":"2014","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Bugatti S, Biggioggero M, Caporali R (2014) Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int 2014:831603","journal-title":"Biomed Res Int"},{"key":"5734_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"5734_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/03009740601089267","volume":"36","author":"M \u00d8stergaard","year":"2007","unstructured":"\u00d8stergaard M, Unkerskov J, Linde L, Krogh NS, Ravn T, Ringsdal VS, Petri A, Andersen LS, Tarp U, Hansen A, Hjardem E, Hetland ML (2007) Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 36:151\u2013154","journal-title":"Scand J Rheumatol"},{"key":"5734_CR11","doi-asserted-by":"publisher","first-page":"m2288","DOI":"10.1136\/bmj.m2288","volume":"370","author":"K Janke","year":"2020","unstructured":"Janke K, Biester K, Krause D et al (2020) Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ 370:m2288","journal-title":"BMJ"},{"key":"5734_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-017-1293-1","volume":"19","author":"M Grabner","year":"2017","unstructured":"Grabner M, Boytsov NN, Huang Q, Zhang X, Yan T, Curtis JR (2017) Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Res Ther 19:92","journal-title":"Arthritis Res Ther"},{"key":"5734_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/acr.23859","volume":"72","author":"AR Karpes Matusevich","year":"2020","unstructured":"Karpes Matusevich AR, Suarez-Almazor ME, Cantor SB, Lal LS, Swint JM, Lopez-Olivo MA (2020) Systematic review of economic evaluations of cycling versus swapping medications in patients with rheumatoid arthritis after failure to respond to tumor necrosis factor inhibitors. Arthritis Care Res 72:343\u2013352","journal-title":"Arthritis Care Res"},{"key":"5734_CR14","doi-asserted-by":"publisher","first-page":"vii42","DOI":"10.1093\/rheumatology\/key195","volume":"57","author":"M Todoerti","year":"2018","unstructured":"Todoerti M, Favalli EG, Iannone F et al (2018) Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology 57:vii42\u2013vii53","journal-title":"Rheumatology"},{"key":"5734_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4081\/reumatismo.2011.155","volume":"63","author":"G Lapadula","year":"2011","unstructured":"Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F, GISEA (2011) GISEA: an Italian biological agents registry in rheumatology. Reumatismo 63:155\u2013164","journal-title":"Reumatismo"},{"key":"5734_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk\u00fd J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"5734_CR17","first-page":"83","volume":"8","author":"W Chan","year":"2013","unstructured":"Chan W (2013) Statistical methods in medical research. Model Assist Stat Appl 8:83\u201384","journal-title":"Model Assist Stat Appl"},{"key":"5734_CR18","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s10067-016-3227-8","volume":"35","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Kaneko Y, Kondo H, Takeuchi T (2016) Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol 35:2829\u20132834","journal-title":"Clin Rheumatol"},{"key":"5734_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","volume":"77","author":"S Henaux","year":"2018","unstructured":"Henaux S, Ruyssen-Witrand A, Cantagrel A, Barnetche T, Fautrel B, Filippi N, Lukas C, Raffeiner B, Rossini M, Degbo\u00e9 Y, Constantin A (2018) Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 77:515\u2013522","journal-title":"Ann Rheum Dis"},{"key":"5734_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68:1\u201325","journal-title":"Arthritis Care Res"},{"key":"5734_CR21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"J-E Gottenberg","year":"2016","unstructured":"Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Liot\u00e9 F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P (2016) Non\u2013TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug. JAMA 316:1172\u20131180","journal-title":"JAMA"},{"key":"5734_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/14397595.2014.953668","volume":"25","author":"T Kobayakawa","year":"2015","unstructured":"Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N (2015) Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Mod Rheumatol 25:251\u2013256","journal-title":"Mod Rheumatol"},{"key":"5734_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","volume":"71","author":"SM Du Pan","year":"2012","unstructured":"Du Pan SM, Scherer A, Gabay C, Finckh A (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71:997\u2013999","journal-title":"Ann Rheum Dis"},{"key":"5734_CR24","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","volume":"71","author":"JJ Gomez-Reino","year":"2012","unstructured":"Gomez-Reino JJ, Maneiro JR, Ruiz J, Rosell\u00f3 R, Sanmarti R, Romero AB, MIRAR Study Group (2012) Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 71:1861\u20131864","journal-title":"Ann Rheum Dis"},{"key":"5734_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Mart\u00ednez Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, Gemmen E, Mpofu C, Chung C, Gylvin LH, Finckh A (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74:979\u2013984","journal-title":"Ann Rheum Dis"},{"key":"5734_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF (2011) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 15:1\u2013278","journal-title":"Health Technol Assess"},{"key":"5734_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semarthrit.2019.06.020","volume":"50","author":"K Lauper","year":"2020","unstructured":"Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordstr\u00f6m DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Gale SL, John M, Luder Y, Courvoisier DS, Gabay C (2020) Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-na\u00efve patients with rheumatoid arthritis. Semin Arthritis Rheum 50:17\u201324","journal-title":"Semin Arthritis Rheum"},{"key":"5734_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jbspin.2019.07.008","volume":"87","author":"G Vial","year":"2020","unstructured":"Vial G, De Pouilly A, Scouppe L et al (2020) Factors influencing the choice of biologic therapy following rituximab in patients with rheumatoid arthritis: a retrospective study using propensity score. Jt Bone Spine 87:43\u201348","journal-title":"Jt Bone Spine"},{"key":"5734_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/kev297","volume":"55","author":"UA Walker","year":"2016","unstructured":"Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordstr\u00f6m DC, Canh\u00e3o H, Tom\u0161i\u010d M, van Vollenhoven R, Gabay C (2016) Rituximab done: what\u2019s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology 55:230\u2013236","journal-title":"Rheumatology"},{"key":"5734_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/annrheumdis-2013-204417","volume":"73","author":"S Das","year":"2014","unstructured":"Das S, Vital EM, Horton S, Bryer D, el-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH (2014) Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 73:909\u2013912","journal-title":"Ann Rheum Dis"},{"key":"5734_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","volume":"81","author":"C Gaujoux-Viala","year":"2014","unstructured":"Gaujoux-Viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X, Nataf H, Saraux A, Trope S, Combe B, French Society for Rheumatology (2014) Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Jt Bone Spine 81:287\u2013297","journal-title":"Jt Bone Spine"},{"key":"5734_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10067-016-3528-y","volume":"36","author":"S Monti","year":"2017","unstructured":"Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R (2017) Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol 36:753\u2013761","journal-title":"Clin Rheumatol"},{"key":"5734_CR33","first-page":"455","volume":"38","author":"E Alemao","year":"2020","unstructured":"Alemao E, Postema R, Elbez Y, Mamane C, Finckh A (2020) Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 38:455\u2013466","journal-title":"Clin Exp Rheumatol"},{"key":"5734_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0300060515593240","volume":"44","author":"P Conigliaro","year":"2016","unstructured":"Conigliaro P, Triggianese P, Chimenti MS, Lucchetti R, Kroegler B, Perricone R (2016) Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab. J Int Med Res 44:53\u201357","journal-title":"J Int Med Res"},{"key":"5734_CR35","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor \u03b1 inhibitor infliximab. Arthritis Rheum 54:3782\u20133789","journal-title":"Arthritis Rheum"},{"key":"5734_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BAC, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05734-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05734-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05734-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T21:58:00Z","timestamp":1632520680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05734-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5734"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05734-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"2 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study has been approved by the local ethical committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}